Adjuvant vinorelbine plus cisplatin versus vinorelbine plus cisplatin plus Endostar [endostatin] in patients with completely resected stage IB-IIIA non-small cell lung cancer (phase III study, randomized, open, multi-center).

Trial Profile

Adjuvant vinorelbine plus cisplatin versus vinorelbine plus cisplatin plus Endostar [endostatin] in patients with completely resected stage IB-IIIA non-small cell lung cancer (phase III study, randomized, open, multi-center).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2012 Preliminary results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.
    • 08 Jun 2010 Interim results from 545 patients presented at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top